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Initial experience in self-monitoring
of intraocular pressure
Emily McGarva1, Jane Farr1, Priya Dabasia2,
John G Lawrenson2,3 and Ian E Murdoch1,3
Abstract
Background/aims: Diurnal variation in intraocular pressure (IOP) is a routine assessment in glaucoma management.
Providing patients the opportunity to perform self-tonometry might empower them and free hospital resource. We
previously demonstrated that 74% of patients can use the IcareV
R
HOME tonometer. This study further explores IcareV
R
HOME patient self-monitoring.
Methods: Patients were trained by standard protocol to use the IcareV
R
HOME rebound tonometer. Patient self-
tonometry was compared to Goldmann applanation tonometry (GAT) over one clinical day. Following this, each patient
was instructed to undertake further data collection that evening and over the subsequent two days.
Results: Eighteen patients (35 eyes) participated. Good agreement was demonstrated between GATand IcareV
R
HOME
for IOPs up to 15mmHg. Above this IOP the IcareV
R
tended to over-read, largely explained by 2 patients with corneal
thickness >600 um. The mean peak IOP during ‘clinic hours’ phasing was 16.7mmHg and 18.5mmHg (p¼ 0.24) over
three days. An average range of 5.0, 7.0 and 9.8mmHg was shown during single day clinic, single day home and three day
home phasing respectively (p¼<0.001). The range of IOP was lower in eyes with prior trabeculectomy (6.1mmHg vs
12.2mmHg). All patients undertook one reading in the early morning at home with an average of 4.8 readings during,
and 3.1 readings after office hours.
Conclusions: This small study shows that self-tonometry is feasible. The findings from home phasing demonstrated
higher peak and trough IOPs, providing additional clinical information. Home phasing is a viable alternative. The cost-
effectiveness of this approach has yet to be addressed.
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Introduction
As intraocular pressure (IOP) is the primary modifiable
risk factor in glaucoma treatment,1 IOP readings are a
critical component of glaucoma management. While
establishing diagnosis and treatment, a patient may
be asked to attend for a full day of IOP measurements
(phasing) as fluctuating and raised IOP are more
marked in those with glaucoma2 and are associated
with primary open angle glaucoma progression.3–6
Day phasing is generally performed with the accept-
ed gold standard Goldmann applanation tonometry
(GAT)7 by a trained healthcare professional (e.g.
nurse, optometrist or doctor) using topical anaesthesia
and a device mounted on a slit lamp. For logistical
reasons, phasing is generally limited to standard clinic
working hours. This means peaks and troughs of IOP,
known to also occur in normal individuals,8,9 may be
missed if they occur outside working hours.
An alternative to clinic day phasing is home moni-
toring. This could allow a wider range of phasing times,
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less interference in the patient’s daily activities and
reduced strain on busy clinics. The first report of
home tonometry in 196510 involved Schi€otz tonometry.
This requires the use of topical anaesthesia, as well as
an additional person to perform the measurement, and
has the potential risk of corneal abrasion.
The concept of self-tonometry was conceived in
1967.11 Despite many subsequent developments, self-
phasing at home has not yet reached the stage of
replacing IOP phasing in the clinical setting. Home
monitoring is now commonplace in relation to the
diagnosis and management of systemic hypertension,12
diabetes13 and many other conditions. The concept of
IOP home monitoring is now more feasible due to the
design of tonometers that do not require topical
anaesthesia.
The IcareVR HOME tonometer is designed specifi-
cally for self-tonometry. This new and updated model
of the IcareVR ONE tonometer uses the same rebound
technology and principles whereby IOP is calculated
from the deceleration of the probe and corneal contact
time.14
The IcareVR HOME includes EyeSmart eye recogni-
tion technology to assign each measurement to the
right or left eye and EasyPos alignment features to
make the device more user friendly.
There have been several studies investigating the
accuracy and usability of IcareVR devices. However, to
date there are few reports of the IcareVR HOME being
used as intended in a ‘home’ setting, away from the
typical clinic environment. This study aimed to evalu-
ate the feasibility of performing self-tonometry for
phasing in a home setting and the clinical usefulness
of performing self-tonometry in this setting by estab-
lishing fluctuations in IOP and the daily peak of IOP. It
also provides further information in relation to the
IcareVR HOME’s self-tonometry readings compared to
in-clinic GAT phasing.
Materials and methods
Patients were recruited using the following inclusion
criteria: aged 18 years or older with a diagnosis of
ocular hypertension (OHT) (healthy disc, full visual
fields (Humphrey HFA 24-2 SITA) and
IOP > 21mmHg on at least two separate occasions),
or open angle glaucoma (OAG), or angle closure glau-
coma (ACG) (pathological cupping of optic disc with
matching visual field loss in the presence of an open or
occludable angle respectively), willing consent to inclu-
sion in the study, and ability to use the IcareVR HOME
tonometer (Icare Finland Oy. Vantaa, Finland).
Exclusion criteria consisted of one or more of the
following: inability to speak fluent English, inability to
reliably use IcareVR HOME tonometer, and ocular
abnormalities likely to give rise to artefactual IOP
measurements (for example severe corneal scarring).
This study was approved by the School of Health
Sciences Research Ethics Committee, City University
of London, and complied with the tenets of the
Declaration of Helsinki. Written and informed consent
was obtained from all participants prior to taking part
in the study.
Patients followed two study phases. Phase one
involved a standardised training protocol that allowed
the patients to build familiarity and competency with the
IcareVR HOME tonometer. This was followed by baseline
data collection including demographic information and
a brief history including previous ocular history.
LogMAR visual acuity was measured with the subject’s
current distance spectacles. Central corneal thickness
(CCT) was recorded using a Pachmate 2 pachymeter
(DGH Technology, Inc. Exton, Pennsylvania, USA).
The training protocol was developed in line with
manufacturer recommendations and is described in
detail in a previous report.15 It is summarised in
Figure 1.
The patient obtained three consecutive IOP measure-
ments with the IcareVR HOME tonometer followed
immediately by one reading taken by an optometrist
and three consecutive GAT measurements, while
masked to the patient’s self-IcareVR HOME results. The
Goldmann dial was set to 10mmHg before each reading
was taken and the median of each set of readings was
used for analysis.16 Patients were classified as competent
in self-tonometry according to the following criteria:
1. The IcareVR HOME reading taken by the optometrist
and the first of the 3 readings taken by the patient
differ by 5mmHg or less.
2. The range (max to min.) of the first 2 readings taken
by the patient is:
a. 5mmHg or less if the first reading is 7–23mmHg
OR
b. 7mmHg or less if the first reading is >23mmHg
3. The positioning of the IcareVR HOME tonometer was
correct during self-use as determined by the
optometrist.
Phase two involved three days of data collection. On
the first day (approximate clinic hours 09:00–16:30)
hourly IOP assessments were made in-clinic. The sub-
ject took three consecutive IcareVR HOME measure-
ments followed by the optometrist taking three
consecutive GAT readings. The Goldmann tonome-
ter’s calibration was verified each day. The subject
was then provided with an IcareVR HOME tonometer,
probes, written information, spare batteries and a feed-
back sheet. The subject was instructed to perform three
consecutive self-tonometry readings at two hourly
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intervals on the same evening as the clinic phasing and
also over a subsequent two day period. It was requested
that patients aimed to include early morning and late
evening measurements. The data collection, outside of
the clinic, is referred to as ‘home phasing’ and encom-
passes the patient performing self-tonometry in a home
environment, as well as any other mobile location that
they felt was appropriate to them. For example, this
could be while they were at work or socialising.
Home phasing IOP data (including time, date and
eye measured) was stored within the tonometer and not
visible to the patient. On return of the tonometer, the
data was downloaded to a computer with IcareVR Link
software for storage and viewing.
Analysis
For all analyses the median IOP reading was taken.
Bland and Altman17 plots were used for the observer
comparison stage of this study. For the comparison of
the continuous variable of IOP, descriptive statistics
were used (average, range, peak and trough) together
with paired t-tests with a p value of 0.05 being taken
as significant (data distribution was checked for nor-
mality prior to this test).
Results
Eighteen patients (35 eyes) completed the observer
comparison phasing day in clinic office hours (100%
training protocol pass rate). Seventeen patients
(34 eyes) carried out home phasing for the subsequent
two days and one patient (2 eyes) for one day. The
demographic and clinical findings for all participants
are shown in Table 1.
A Bland Altman plot comparing GAT and IcareVR
Home shows good agreement up to 15mmHg then
suggests an over-read for the IcareVR HOME for
higher IOPs (Figure 2). The over-read increases with
increasing IOP (r2¼ 0.29 p< 0.001). This finding is in
part, but not wholly, explained by two patients (one of
whom had prior trabeculectomy) with an average CCT
Figure 1. Standardised training procedure for the use of the IcareV
R
HOME tonometer.
Table 1. Clinical data from the 18 patients (35 eyes) who
completed phase one and phase two.
Measurement Mean (SD)
Visual Acuity (logMAR) 0.05 (0.15)
Age (years) 69 (6.6)
Gender 39% female
Diagnosis 14 Open Angle Glaucoma
1 Angle Closure Glaucoma
3 Ocular Hypertension
Prior Trabeculectomy 7 eyes (6 patients)
Mean Refractive Error (DS) –0.08 (2.38)
Vertical Palpebral Aperture (mm) 10.1 (1.5)
CCT (mm) 543 (34)
GAT IOP (mmHg) 13.4 (4.8)
iCare IOP (mmHg) 14.3 (6.1)
CCT: Central corneal thickness; GAT: Goldmann applanation tonometry;
IOP: intraocular pressure. DS: Dioptres.
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of >600um, which exceeds the recommended range
for IcareVR .
The mean peak IOP recorded with the IcareVR
HOME during clinic self-tonometry phasing was
16.7mmHg. The mean peak with all day recording
was marginally higher (17.1mmHg, p¼ 0.02). The
mean peak using data from three days recording was
higher again (18.5mmHg p< 0.001).
The range of IOP recorded was then examined.
Single day clinic self-tonometry phasing with the
IcareVR HOME showed an average range of
5.0mmHg. All day recording showed a larger range
of 7.0mmHg (p< 0.001) and three day readings
showed a larger range again of 9.8mmHg (p< 0.001).
Table 2 shows the variation by diagnosis and surgi-
cal intervention. Of note is that those with OHT had
the highest range in IOP (12.2mmHg, p¼ 0.001)
whereas the eyes with prior trabeculectomy surgery
had the lowest (6.1mmHg, p¼ 0.29).
The timings of IOP measurements in the clinic and
home settings were compared. 6-7 readings were taken
between 09:00 and 16:30 in the clinical setting. When
performing home phasing all patients undertook one
reading in the morning, generally between 07:00 and
08:00, with an average of 4.8 readings during standard
office hours (i.e. 09:00–17:00) and 3.1 readings taken
after 17:00. The average peak IOP was highest during
standard office hours (16.4mmHg), being 14.7mmHg
in early morning and 15.1mmHg in the evening.
During home phasing a total of 306 self-tonometry
readings were taken. 38 (12.4%) were prior to clinic
office hours, 153 (50%) during office hours and 115
(37.6%) after office hours.
Discussion
All patients entering the study successfully completed
the self-tonometry training protocol (phase one) in at
least one eye and subsequently all were classed as com-
petent in self-tonometry and were able to move onto
phase two with data collection. Our previous study
found that 74% of subjects were able to correctly per-
form self-tonometry with the IcareVR HOME.15 This
also aligns with a similar study that found a 73%
rate of success in training.18 These studies did not
investigate ‘home’ setting self-tonometry.
It is likely that this study has some bias inherent in
the phase one training pass rates of 100%. This bias
may stem from a high level of patient motivation from
the outset due to their intended commitment to the
three days of home phasing. In addition, all patients
had steady hands, a sufficiently large palpebral aper-
ture and a reasonable level of vision that allowed
them to competently perform self-tonometry in at
least one eye.
Although recent studies have reported that the
IcareVR HOME tonometer can be correctly used by
the majority of patients,15,18–20 there have been
Figure 2. Bland Altman agreement between GAT and IcareV
R
HOME. The horizontal axis is the mean reading and the vertical axis is
the self IcareV
R
– Goldmann reading. The horizontal line shows the average result by 5 mmHg group. A jitter plot is used to highlight
multiple corresponding data points. The triangular points represent those taken from eyes with CCT > 600 mm.
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conflicting results published in relation to the
device’s agreement with GAT. In relation to the
IcareVR ONE tonometer, previous studies have
reported variable agreement between self-tonometry
and GAT.21–23 The agreement is generally good
(þ/1.2mmHg< 20mmHg and þ/2.2mmHg
20mmHg) within the advised established corneal thick-
nesses between 500 and 600um.24–28 The first part of this
study is a simple observer comparison study between self-
tonometry with the updated IcareVR model, IcareVR
HOME, and ‘gold standard’ GAT.
We observed good agreement between the IcareVR
HOME and GAT at low IOPs, but with a progressive
over-reading for the IcareVR HOME for IOPs greater
than 15mmHg. This could be partly explained by the
inclusion of two patients with a CCT of >600 um, and
therefore outside the recommended range of
500-600um for the device. This is also in agreement
with previous reports, which found IcareVR devices to
produce an overestimation with higher IOPs, largely
due to thick corneas.15,19,24,25,29,30
In order for ‘home’ IOP monitoring to become com-
monplace, the process must provide additional benefits
over those provided by clinic GAT phasing. One such
benefit is the potential for extra readings out with clinic
hours. This could provide additional relevant informa-
tion that may influence a patient’s diagnosis or man-
agement. On the days when the patients performed
home phasing without supervision (i.e. days two and
three) only half of the readings were taken within stan-
dard office hours (i.e. 09:00–17:00). These readings out
with standard office hours revealed an increase in the
peak IOP recorded, (single day clinical hour phasing
peak was 16.7mmHg, vs 18.5mmHg over three days
home phasing (p¼ 0.24)). This is in agreement with
Querat and Chen31 who noted 16% of 46 subjects
undertaking self-tonometry had IOP peaks outside
clinic hours. In addition the range of IOPs recorded
were almost twice as large with home monitoring
(range of 9.8mmHg with home phasing vs 5.0mmHg
with clinic hours). There are several studies that have
shown a greater fluctuation in the range of IOPs when
measured out of office hours.32,33 Arora et al.34 2015
identified that, for glaucoma patients, the mean diurnal
IOP and IOP fluctuations with GAT (07:00–22:00)
were greater compared to standard office hours
(09:00–17:00), and peak IOP measurements occurred
outside office hours in two-thirds of patients. Our
study identified a higher range of IOPs compared to
Arora et al 2015, when comparing home phasing
(00:00-24:00) and clinic hours phasing (09:00–16:30).
This is possibly due to the greater time range available
to the patients completing home phasing within our
study. A study using the IcareVR ONE also identified
higher IOP spikes outside office hours, with 50% of
patient peak IOP values occurring outside office
hours.35
Although in this study no evaluation was possible in
regards to the accuracy of self-tonometry when out of
the clinic and away from clinician supervision, it is
worth noting that all 18 patients were classed as com-
petent within office hours and their self-administered
tonometry measurements were satisfactorily compara-
ble to the optometrists IcareVR HOME measurement
and GAT.
The larger IOP range from our findings concurs with
the conclusion that home tonometry is a valid method
for detecting diurnal fluctuation outside normal clinic
hours. In a recently published study by Huang et al.36
27 patients completed self-tonometry over 40 days.
Using four readings per day, they reported ‘correlation’
of the IOP variation comparing the first day, first two
days, first three days and so on with the results over
40 days. Not-surprisingly they reported increasing
agreement as the number of measurement days
increased with the range of IOP recorded over
40 days. Moderately good agreement was found
between three days of measurements compared with
40 with a further small increase to seven days after
which any increase was minimal.36
Table 2. IOP variation by diagnosis and surgical intervention, from self-tonometry with the IcareV
R
HOME tonometer. Paired t-tests
compare the ranges between self-tonometry performed during the clinic office hours phasing and all day self-tonometry measure-
ments within individuals.
Diagnosis Surgery
Self-tonometry
office range IOP
(mmHg)
Self-tonometry
single day range
IOP (mmHg)
Peak range
IOP (mmHg)
OHT (N¼ 3) 4.4 9.2 (p¼ 0.02) 12.2 (p¼ 0.001)
ACG (N¼ 1) 4.5 6.2 9.5
OAG (N¼ 14) No trabeculectomy (N¼ 7) 5.4 7.3 (p< 0.001) 10.5 (p< 0.001)
Trabeculectomy (N¼ 7) 4.7 4.5 (p¼ 0.36) 6.1 (p¼ 0.09)
All OAG (N¼ 14) 5.2 6.6 (p< 0.001) 9.3 (p< 0.001)
IOP: intraocular pressure; OHT: ocular hypertension; ACG: angle closure glaucoma; OAG: open angle glaucoma.
McGarva et al. 5
An additional key finding from this study was the
consistency of IOP range in those eyes that had prior
trabeculectomy surgery. The range did not increase
with greater observation timing. This suggests the
home tonometry may be generating accurate readings
and also confirms prior reports of the effect of trabe-
culectomy surgery on IOP range.37
Cost effectiveness
The cost effectiveness of implementing a system in
which home phasing with self-tonometry replaces in-
clinic phasing needs to be assessed. From a patient per-
spective, the time taken to learn self-tonometry versus
the time taken to do all day phasing in a clinic seems a
clear benefit. For the working population in particular,
the time required for clinic phasing can be extremely
inconvenient, whereas self-phasing may enable patients
to continue their daily activities with minimal disrup-
tion. However, from the clinician perspective the time
considerations may not be dissimilar.
The proportion of patients who successfully com-
plete phase one should also be considered. Our previ-
ous study found that 74% of subjects were able to
correctly perform self-tonometry.15 This agrees with
other similar reports with the IcareVR HOME.18
Additional considerations include the overheads of
clinical space (for example, patients need to have a
place to wait during all day phasing), equipment main-
tenance and provision (slit lamp and GAT vs IcareVR
HOME), consumable use (anaesthetic drops and GAT
tonometer heads vs probes and batteries for the IcareVR
HOME). We believe many of these will not significant-
ly vary between the two methods, therefore suggesting
that the use of self-tonometry does not currently
appear to be advantageous in terms of overall cost
differences.
In conclusion, we previously demonstrated that 74%
of patients can use the IcareVR HOME tonometer suc-
cessfully.15 With this latest study we have built on those
findings, demonstrating that self-tonometry within a
‘home’ environment is possible and a viable alternative
to in-office clinic GAT IOP phasing. Furthermore, the
findings from this study suggest self-tonometry home
phasing is beneficial in demonstrating higher peak and
trough IOPs, thereby providing more detailed ocular
health information. The cost-effectiveness of this
approach has yet to be fully addressed, but initial
review indicates that cost comparisons are similar.
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